Biotechnology Startup Testing Super Bees

A biotechnology startup called BeeFlow has found a solution to save honeybees from dying.

“Almost 90 percent of wild plants are dependent on insect pollination. If we don’t act to save these remarkable creatures, our world will be a less colorful and more lonesome place,” said Kelsey Kopec, a native pollinator researcher at the Center for Biological Diversity.

Honeybees have come under severe pressure in the last decade. Populations of more than 700 North American bee species are dying because of habitat loss and pesticide use.

BeeFlow’s goal is to develop healthy and intelligent bees to solve the population decline stemming from the colony collapse disorder (CCD). The Environmental Protection Agency and the National Pesticide Information report that CCD is a major problem for beekeepers.

CCD occurs when the majority of worker bees in a colony disappear. The remaining bees in the hive cannot sustain themselves without worker bees and eventually die. Researchers have found that parasites, inadequate nutrition, bee pesticide poisoning, and stress from management practices compel bees to flee their current locations.

According to CGTN, BeeFlow has developed solutions that can help bees become stronger and stay at their hives. One of the formulas is an organic compound that can boost bee immune systems. The second product is designed to help bees pollinate specific crops.

In short, the company creates organic molecules compounds to enhance the immune system of bees and teach them to pollinate targeted crops.

BeeFlow has already conducted tests in Argentina, where the formulas helped farmers increase yields between 20% to 90%. It will now test its products at the Simba Farms almond groves in California.

The startup is based in Argentina and San Francisco. The team is currently working at an IndieBio lab in San Francisco. IndieBio is the world’s largest accelerator for biotech startups. BeeFlow is also supported by GridX Exponential – the first science-based company builder in Latin America.


Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’